Sign in
ALLK Stock Price, Chart, Stats & News
Allakos Inc.
Save
29.74M
Market cap
–
Current P/E
–
Forward P/E
ALLK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 27.56% |
Operating margin | -1214.22% |
Pretax margin | -1135.68% |
Net margin | -1135.68% |
Effective tax rate | – |
ROA | -74.19% |
ROE | -64.02% |
D/E | – |
Interest coverage ratio | – |
ALLK valuation
P/E | – |
P/S | 7.65x |
P/B | 0.53x |
P/CF | -0.41x |
P/FCF | -0.41x |
P/OCF | -0.41x |
PEG | -0.02x |
EV multiple | -0.94x |
About
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody.
Similar securities
Based on sector and market capitalization
Report issue